Evidence map›Paper›PMID 42066658›Full record

ArticleLung cancer (Amsterdam, Netherlands)2026

Epidermal growth factor receptor-targeted near-infrared photoimmunotherapy for malignant pleural mesothelioma.

Miyu Kano, Aki Furusawa, Seiichiro Takao, Motofumi Suzuki, Makoto Kano, Hiroshi Yamamoto, Peter L Choyke, Hisataka Kobayashi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Lung cancer (Amsterdam, Netherlands), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Miyu KanoMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
Aki FurusawaMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
Seiichiro TakaoMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
Motofumi SuzukiMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
Makoto KanoMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
Hiroshi YamamotoMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
Peter L ChoykeMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
Hisataka KobayashiMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA. Electronic address: kobayash@mail.nih.gov.

Funding

Cancer-cell specific therapy: photo-immunotherapyZIABC011513 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KOBAYASHI, HISATAKA · 2013 to 2025
$15.5M
Intramural NIH HHS ZIA BC011513
6 · The paper itself

Abstract

Malignant pleural mesothelioma (MPM) is a rare, aggressive cancer mostly associated with asbestos exposure. Effective treatments are limited, and the prognosis is extremely poor. Therefore, the development of novel therapeutic approaches is highly desirable. Near-infrared photoimmunotherapy (NIR-PIT) is a newly developed cancer treatment that specifically kills target cells. It utilizes an antibody-IRDye700DX conjugate that binds target tumor cells. After near-infrared light irradiation of the tumor, rapid and highly selective cell damage results in immunogenic cell death. Anti-epidermal growth factor receptor (EGFR) antibody-IRDye700DX conjugate has already been approved in Japan for the treatment of head and neck cancer with near-infrared laser light activation. EGFR overexpression in MPM makes it a promising candidate for EGFR-targeted NIR-PIT, but its efficacy has not been reported previously. In this study, we investigated the therapeutic effects of NIR-PIT targeting EGFR using an MPM xenograft mouse model. In vitro, three MPM cell lines (NCI-H28, NCI-H226, and MSTO-211H) showed EGFR overexpression on the cell surface. EGFR-targeted NIR-PIT induced cell death in a dose-dependent manner in all MPM cell lines. In vivo, EGFR expression was verified, and anti-EGFR antibody binding was observed in both NCI-H226 and MSTO-211H tumors. After EGFR-targeted NIR-PIT, histological analysis demonstrated cancer cell death which significantly suppressed tumor growth in both tumor models and significantly extended survival in NCI-H226 tumor-bearing mice. Thus, these results suggest that EGFR-targeted NIR-PIT could be a promising treatment approach for MPM.

Indexed as

ErbB ReceptorsImmunotherapyLung NeoplasmsMesotheliomaPhototherapyPleural NeoplasmsAnimalsCell Line, TumorDisease Models, AnimalFemaleHumansImmunoconjugatesIndolesInfrared RaysMesothelioma, MalignantMiceErbB ReceptorsImmunoconjugatesIndolesCancerEpidermal growth factor receptorMalignant pleural mesotheliomaNear-infrared photoimmunotherapyPreclinical model

Identifiers

PMID42066658
PMCPMC13274800

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.